Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythropoietin and iron

G Sunder-Plassmann1, W H Hörl

  • 1Department of Medicine, University of Vienna, Austria.

Clinical Nephrology
|March 1, 1997
PubMed
Summary

Iron status is crucial for patients on recombinant human erythropoietin (r-HuEPO) therapy. Proper iron supplementation improves treatment efficacy and reduces costs, but intravenous iron requires careful monitoring to avoid side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Clinical pharmacology and therapeutics·2018
Same author

Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease Patients.

Hemodialysis international. International Symposium on Home Hemodialysis·2017
Same author

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Clinical pharmacology and therapeutics·2016
Same author

[Thrombotic microangiopathy : Relevant new aspects for intensive care physicians].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2016
Same author

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Lancet (London, England)·2009
Same author

An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid.

The pharmacogenomics journal·2009

Area of Science:

  • Nephrology
  • Hematology
  • Pharmacology

Background:

  • Iron status evaluation is critical for end-stage renal disease (ESRD) patients undergoing recombinant human erythropoietin (r-HuEPO) therapy.
  • Iron deficiency, both absolute and functional, is a primary cause of poor response to r-HuEPO treatment.

Purpose of the Study:

  • To highlight the importance of iron status assessment in ESRD patients on r-HuEPO therapy.
  • To outline appropriate iron supplementation strategies to optimize r-HuEPO treatment and reduce costs.

Main Methods:

  • Review of current literature and clinical guidelines on iron management in ESRD patients.
  • Analysis of iron deficiency parameters (ferritin, transferrin saturation, hypochromic red blood cells) and their impact on r-HuEPO response.

Main Results:

  • Absolute iron deficiency (ferritin < 100 µg/L) and functional iron deficiency (normal/high ferritin, TSAT < 20%, hypochromic RBC > 5%) impair r-HuEPO effectiveness.
  • Oral iron is recommended for predialysis and peritoneal dialysis patients with ferritin > 100 µg/L.
  • Intravenous (IV) iron is preferred for hemodialysis patients, but overtreatment should be avoided due to potential side effects.

Conclusions:

  • Optimizing iron status is essential for improving r-HuEPO therapy outcomes in ESRD patients.
  • Tailored iron supplementation strategies (oral vs. IV) based on dialysis modality and iron levels can reduce r-HuEPO dosage and healthcare costs.
  • Vigilance regarding potential adverse effects of IV iron, including neutrophil impairment and cardiovascular risks, is necessary to prevent overtreatment.

Related Experiment Videos